1. Age: 18-70 years;

2. Type 2 diabetes mellitus;

3. Not used antidiabetic drugs within 3 months;

4. HbA1c(7-10%);

5. Presence of fatty liver disease (hepatic fat content ≥ 20% by quantitative ultrasonography);

6. Female subjects：post-menopausal women, take contraceptive measures three months before the test screening and can persist throughout the experimental period;

7. Body mass index (BMI) 20-35kg/m2, and stable Weight 3 months(less than 10% volatility);

8. patients signed the informed consent.

1. Used antidiabetic drugs or any other possible hepatic steatosis associated with drugs within the past three months;

2. Suffering from pancreatitis or other pancreatic diseases or have other similar history;

3. GLP-1 analogs or sulfonylurea allergy history;

4. Liver dysfunction (aspartate aminotransferase ≥ 2.5 times of the normalupper limit);

5. Moderate to severe renal insufficiency (eGFR<60ml/min/1.73m2,calculated according to MDRD);

6. Female subjects drinking> 14 units / week; male subjects drinking> 21 units/week;

7. A history of metabolic or autoimmune liver diseases or viral hepatitis diseases;

8. A history of medullary thyroid carcinoma, multiple endocrine neoplasia 2 or family history;

9. Congestive heart failure (NYHA grade Ⅲ - Ⅳ grade);

10. Severe gastrointestinal diseases;

11. Other serious concomitant diseases;

12. Pregnant or planning pregnancy;

13. The researchers believe that the subjects with proliferative retinopathy or macular degeneration need urgentl treatment;

14. Subjects are using unknown ingredients or non herbal medicine preparations or local medicine, researchers believe that during the test the dose of traditional Chinese medicines can not be adjusted or disabled.